Abstract: The present invention relates to a method for preparing chlorophyll-a and chlorin e6. This invention extracts chlorophyll-a by use of undisrupted chlorella cells themselves, thereby preparing chlorin e6 from the chlorophyll-a extract. The high contents of chlorophyll-a may be obtained by the pretreatment procedure of chlorella cells themselves selected in this invention. The present method is performed according to relatively simple procedures, and is suitable in the mass production of chlorin e6.

Abstract: A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from above about 20% to 50% by weight of the composition, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 85% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharma-ceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipien

Abstract: The present invention discloses a method for deactivating ISR and a mobility management unit. Wherein the above method includes: when an ISR deactivation is needed to be performed, the mobility management unit judging whether to perform the following operation by the S-GW according to reasons of the ISR deactivation: the mobility management unit sends a request message of deleting bearer to the S-GW, and carries, in the request message, an identifier which is used to instruct the S-GW to initiate the bearer deletion to the other mobility management unit associated with the ISR function activation; or the mobility management unit notifies the other mobility management unit associated with the ISR function activation to perform the ISR deactivation. The synchronization between the bearer deletion and the network element state in the ISR function deactivation scenarios can be realized by the above technical scheme.

Abstract: The present invention relates to immobilization compounds and methods useful for the identification of JAK interacting compounds or for the purification or identification of JAK.

Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.

Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.

Abstract: This invention relates generally to detection devices having one or more small wells each surrounded by, or in close proximity to, an NMR micro coil, each well containing a liquid sample with magnetic nanoparticles that self-assemble or disperse in the presence of a target analyte, thereby altering the measured NMR properties of the liquid sample. The device may be used, for example, as a portable unit for point of care diagnosis and/or field use, or the device may be implanted for continuous or intermittent monitoring of one or more biological species of interest in a patient.

Abstract: This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic conditions associated therewith, including hepatitis C.

Abstract: The invention features methods and devices for the detection of biomarker complexes and their components and for the sequential detection of multiple epitopes of a biomarker. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease.

Abstract: A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from 0.

Abstract: The present invention discloses a GSM/CDMA dual-mode mobile phone and method of the same for inhibiting a GC mutual interference, wherein the mobile phone comprises a dual-port antenna connected respectively with a duplexer and a GSM RF circuit and configured to access the signals of the GSM and the CDMA; a RF switch provided in the CDMA RF receiving circuit, wherein the RF switch is controlled by a GSM baseband chip and configured to cut off a CDMA signal (i.e., cutting off a receiving path of the CDMA) transmitted/received by the dual-port antenna when a GSM operational frequency and a CDMA operational frequency belong to close frequency band during a transmitting timeslot of the GSM, to enhance the isolation between a GSM signal and a CDMA signal.

Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.

Abstract: An improved calcium phosphate delivery vehicle or adjuvant with incorporated adjuvanticity enhancing means and methods of producing same are disclosed. The adjuvant can be fabricated to desired formulations as appropriate and based on the intended purpose. Particle sizes can be adjusted to enhance adjuvant activity. Other supplemental materials may be added as desired and in appropriate proportions to selectively elicit preferred components of the immune system and to enhance the adjuvant's effect on the host response.

Abstract: This invention relates generally to detection devices having one or more small wells each surrounded by, or in close proximity to, an NMR micro coil, each well containing a liquid sample with magnetic nanoparticles that self-assemble or disperse in the presence of a target analyte, thereby altering the measured NMR properties of the liquid sample. The device may be used, for example, as a portable unit for point of care diagnosis and/or field use, or the device may be implanted for continuous or intermittent monitoring of one or more biological species of interest in a patient.

Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc

Abstract: A method for releasing buffered data of a Serving Gateway is disclosed? the Serving Gateway (Serving GW) buffers downlink data sent to a user and sends a data notification message to a Mobility Management Entity (MME); after receiving the data notification message, the MME initiates a paging to the user and sets a paging timer, if the paging timer expires and no paging response of the user is received, the MME sends a notification message to the Serving GW to inform the Serving GW that there is no paging response from the user; and after receiving the notification message, the Serving GW releases the buffered downlink data. With this method, the Serving GW can release buffered data in time without causing wrong release of the buffered data, so the system efficiency can be improved.

Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.

Abstract: The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.